a111218q3announcement_image.jpg

     
Oncolytics Biotech® Reports 2018 Third Quarter Financial Results
and Provides Corporate Update

- Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications -

- Management to host webcast and conference call today at 8:30 a.m. ET -

CALGARY, AB and SAN DIEGO, CA November 12, 2018 -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced financial results and operational highlights for the quarter ended September 30, 2018. All dollar amounts are Canadian unless otherwise noted.

“The clinical progress and mechanistic understandings achieved with pelareorep thus far in 2018 lay the ground work for a transformational 2019. We continue to advance towards a registration study in metastatic breast cancer as we prepare to initiate our AWARE-1 window of opportunity clinical study with pelareorep and Roche’s checkpoint inhibitor, Tecentriq, in breast cancer patients,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “Although we originally believed that pelareorep acts foremost as a lytic agent directly killing tumor cells, we have learned pelareorep replicates efficiently in cancer cells to produce double stranded RNA and trigger an immune response to the tumor by stimulating and recruiting NK cells and T cells to target the tumor. This quarter we presented additional data confirming pelareorep stimulates expression of PD-L1 on tumor cells, thereby transforming those tumor cells into targets for the highly valued immuno-oncology checkpoint inhibitors. This expanded focus on innate and adaptive immune response better allows us to prepare for our planned studies in metastatic breast cancer, to validate recently identified therapeutic biomarkers for pelareorep, and to efficiently explore the potential for pelareorep to extend the effectiveness of checkpoint inhibitors into additional patient populations.”

Selected highlights since July 1, 2018

Clinical Updates
Established plans with pelareorep to advance the phase 3 metastatic breast cancer program and for expansion into combination trials with checkpoint inhibitors to enlist pelareorep’s immune effects and to seek validation of key therapeutic and prognostic biomarkers.
Clinical trials announced in 2018 include:
o
AWARE-1 window of opportunity (WOO) study with pelareorep in combination with Roche’s Tecentriq® in breast cancer.
o
Pelareorep plus Merck’s anti-PD-1 checkpoint inhibitor Keytruda® in pancreatic cancer.
o
Pelareorep plus Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor Opdivo® in multiple myeloma.
o
Pelareorep plus Merck’s anti-PD-1 checkpoint inhibitor Keytruda in multiple myeloma.
Announced a Master Clinical Supply Agreement with F. Hoffmann-La Roche Ltd (Roche) to supply Tecentriq for use in the company’s clinical development program.
Presented positive phase 2 clinical trial results for pelareorep in the treatment of patients with KRAS mutant metastatic colorectal cancer at the European Society for Medical Oncology (ESMO) 2018 Congress. Thirty-six patients received treatment with FOLFIRI/B (irinotecan, fluorouracil, leucovorin, plus bevacizumab) and pelareorep. The six patients receiving treatment with the recommended study dose had progression free survival of 65.6 weeks and an overall survival of 107.5 weeks. Study results exceeded expectations when compared to analogous historical data.




Announced a publication demonstrating that intravenously delivered oncolytic viruses, including pelareorep, effectively target tumors even in the presence of neutralizing antibodies. A publication in Cancer Immunology Research showed that pelareorep, a systemically delivered oncolytic reovirus, can destroy tumor cells via a monocyte-mediated process even after the virions have been exposed to antibodies designed to neutralize the reovirus.

Corporate Updates
Entered into a common stock purchase agreement for up to US$26.0 million with Lincoln Park Capital Fund, LLC.
Announced a US$30.0 million At-the-Market facility with Canaccord Genuity.

Anticipated Milestones
Initiate a phase 2 study with pelareorep in combination with Merck’s Keytruda in advanced pancreatic cancer in Q4 2018*.
Initiate a phase 1 study with pelareorep in combination with Bristol-Myers Squibb’s Opdivo in multiple myeloma in Q4 2018*.
Initiate AWARE-1, a phase 1b WOO study with pelareorep in the neoadjuvant breast cancer setting in Q1 2019.
Initiate a phase 1b study with pelareorep in combination with Merck’s Keytruda in multiple myeloma in Q1 2019*.
Data from AWARE-1 study with pelareorep in breast cancer mid-2019.    
Initiate registration study with pelareorep in mBC – guidance to be provided after AWARE-1 data is available.
Preliminary data from MUK eleven study with pelareorep in multiple myeloma mid-2019*.    

* Guidance provided by principle investigator

Financial
At September 30, 2018, the company reported $16.2 million in cash and cash equivalents.
As at November 8, 2018, the company had an unlimited number of authorized common shares with 17,059,123 common shares issued and outstanding, 16,443,500 warrants exercisable into 1,730,894 common shares with a $9.025 strike price and 1,093,407 options and share units.
Operating expense for the third quarter of 2018 was $1.5 million compared to $1.3 million for the prior year period. R&D expense in the third quarter 2018 was $1.9 compared to $1.7 million for the third quarter of 2017.
The net loss for the third quarter of 2018 was $3.3 million or $0.20 per share compared to a net loss of $3.0 million or $0.20 per share for the period one year ago, on a consolidated basis.

Webcast and Conference Call
Oncolytics management will host a conference call for Analysts and Institutional Investors at 8:30 a.m. ET today, Monday, November 12, 2018. The live call may be accessed by dialing (888) 231-8191 for callers in North America.  Overseas callers should contact investor relations for the toll-free dial information for their country.  A replay of this call will be available approximately two hours after the call is ended at 855-859-2056, using the replay code 6463668 and will be available for six months. 

A live audio webcast of the call will be accessible on the Investor Relations page of Oncolytics' website at www.oncolyticsbiotech.com and will be archived for six months.


ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(unaudited)
As at
September 30,
2018
$
December 31,
2017
$
Assets
 
 
Current assets
 
 
Cash and cash equivalents
16,214,347

 
11,836,119

 
Contract receivable

 
4,767,100

 
Other receivables
56,895

 
37,726

 
Prepaid expenses
1,450,030

 
1,176,063

 
Total current assets
17,721,272

 
17,817,008

 
Non-current assets
 
 
Property and equipment
428,588

 
333,441

 
Total non-current assets
428,588

 
333,441

 
 
 
 
Total assets
18,149,860

 
18,150,449

 
Liabilities And Shareholders’ Equity
 
 
Current Liabilities
 
 
Accounts payable and accrued liabilities
2,239,514

 
3,684,023

 
Contract liability
927,400

 
1,545,645

 
Other liabilities
76,529

 

 
Total current liabilities
3,243,443

 
5,229,668

 
Non-current liabilities
 
 
Contract liability
5,802,887

 
4,636,935

 
Other liabilities
54,128

 

 
Total non-current liabilities
5,857,015

 
4,636,935

 
 
 
 
Total liabilities
9,100,458

 
9,866,603

 
Shareholders’ equity
 
 
Share capital
  Authorized: unlimited
  Issued:
September 30, 2018 – 16,915,325
December 31, 2017 – 141,805,722 pre-consolidation
December 31, 2017 – 14,926,840 post-consolidation
283,742,409

 
271,710,138

 
Warrants
3,617,570

 
3,617,900

 
Contributed surplus
27,894,420

 
27,028,238

 
Accumulated other comprehensive income
459,142

 
373,730

 
Accumulated deficit
(306,664,139

)
(294,446,160

)
Total shareholders’ equity
9,049,402

 
8,283,846

 
Total liabilities and equity
18,149,860

 
18,150,449

 




ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(unaudited)
 
Three Month Period Ending September 30, 2018
$
Three Month Period Ending September 30, 2017
$
Nine Month Period Ending September 30, 2018
$
Nine Month Period Ending September 30, 2017
$
 
 
 
 
 
Expenses
 
 
 
 
Research and development
1,929,405

 
1,726,726
 
6,909,713
 
6,913,470
 
Operating
1,468,262

 
1,309,607
 
4,869,617
 
4,054,450
 
Loss before the following
(3,397,667

)
(3,036,333
)
(11,779,330
)
(10,967,920
)
Interest
61,880

 
31,759
 
109,308
 
96,637
 
Loss before income taxes
(3,335,787

)
(3,004,574
)
(11,670,022
)
(10,871,283
)
Income tax (expense) recovery
(79

)
168
 
(547,957
)
16
 
Net loss
(3,335,866

)
(3,004,406
)
(12,217,979
)
(10,871,267
)
Other comprehensive (loss) income items that may be reclassified to net loss
 
 
 
 
Translation adjustment
(49,238

)
(126,846
)
85,412
 
(192,334
)
Net comprehensive loss
(3,385,104

)
(3,131,252
)
(12,132,567
)
(11,063,601
)
Basic and diluted loss per common share
(0.20

)
(0.20
)
(0.78
)
(0.80
)
Weighted average number of shares (basic and diluted)
16,540,612

 
14,685,871
 
15,646,117
 
13,625,411
 























ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(unaudited)
 
Share Capital
$
Warrants
$
Contributed Surplus
$
Accumulated Other Comprehensive Income
$
Accumulated Deficit
$
Total
$
As at December 31, 2016
262,321,825

 

 
26,643,044

 
554,060

 
(278,829,309

)
10,689,620
 
Net loss and other comprehensive loss

 

 

 
(192,334

)
(10,871,267

)
(11,063,601
)
Issued pursuant to "At the Market" agreement
1,479,065

 

 

 

 

 
1,479,065
 
Issued pursuant to public offering
7,893,600

 
3,617,900

 

 

 

 
11,511,500
 
Issued pursuant to stock option plan
536,949

 

 
(193,509

)

 

 
343,440
 
Share based compensation

 

 
438,044

 

 

 
438,044
 
Share issue costs
(1,331,770

)

 

 

 

 
(1,331,770
)
As at September 30, 2017
270,899,669

 
3,617,900

 
26,887,579

 
361,726

 
(289,700,576

)
12,066,298
 
 
 
 
 
 
 
 
As at December 31, 2017
271,710,138

 
3,617,900

 
27,028,238

 
373,730

 
(294,446,160

)
8,283,846
 
Net loss and other comprehensive income

 

 

 
85,412

 
(12,217,979

)
(12,132,567
)
Issued pursuant to "At the Market" agreement
553,650

 

 

 

 

 
553,650
 
Issued pursuant to public offering
11,606,882

 

 

 

 

 
11,606,882
 
Issued pursuant to Common Stock Purchase Agreement
1,906,152

 

 

 

 

 
1,906,152
 
Issued pursuant to stock option plan
178,322

 

 
(66,635

)

 

 
111,687
 
Issued pursuant to warrant agreement
1,747

 
(330

)

 

 

 
1,417
 
Share based compensation

 

 
932,817

 

 

 
932,817
 
Share issue costs
(2,214,482

)

 

 

 

 
(2,214,482
)
As at September 30, 2018
283,742,409

 
3,617,570

 
27,894,420

 
459,142

 
(306,664,139

)
9,049,402
 








ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
 
Three Month Period Ending September 30, 2018
$
Three Month Period Ending September 30, 2017
$
Nine Month Period Ending September 30, 2018
$
Nine Month Period Ending September 30, 2017
$
 
 
 
 
 
Operating Activities
 
 
 
 
Net loss for the period
(3,335,866

)
(3,004,406

)
(12,217,979

)
(10,871,267

)
Depreciation - property and equipment
26,698

 
20,591

 
67,682

 
70,315

 
Share based compensation
236,607

 
148,447

 
932,817

 
438,044

 
Unrealized foreign exchange loss (gain)
82,643

 
(6,414

)
(19,702

)
(119,058

)
Onerous lease contract
67,588

 

 
67,588

 

 
Amortization - lease incentive liability
12,494

 

 
12,494

 

 
Net change in non-cash working capital
(596,779

)
(331,590

)
3,630,991

 
(1,186,142

)
Cash used in operating activities
(3,506,615

)
(3,173,372

)
(7,526,109

)
(11,668,108

)
Investing Activities
 
 
 
 
Acquisition of property and equipment
(40,094

)
(9,451

)
(120,156

)
(95,337

)
Redemption of short-term investments

 

 

 
2,088,800

 
Cash (used in) provided by investing activities
(40,094

)
(9,451

)
(120,156

)
1,993,463

 
Financing Activities
 
 
 
 
Proceeds from "At the Market" equity distribution agreement

 
733,171

 
520,315

 
1,292,698

 
Proceeds from public offering

 

 
10,188,526

 
10,366,098

 
Proceeds from Common Stock Purchase Agreement
1,143,361

 

 
1,143,361

 

 
Proceeds from exercise of options
87,777

 
48,090

 
111,687

 
343,440

 
Proceeds from exercise of warrants

 

 
1,417

 

 
Cash provided by financing activities
1,231,138

 
781,261

 
11,965,306

 
12,002,236

 
(Decrease) increase in cash
(2,315,571

)
(2,401,562

)
4,319,041

 
2,327,591

 
Cash and cash equivalents, beginning of period
18,741,347

 
16,676,298

 
11,836,119

 
12,034,282

 
Impact of foreign exchange on cash and cash equivalents
(211,429

)
(241,092

)
59,187

 
(328,229

)
Cash and cash equivalents, end of period
16,214,347

 
14,033,644

 
16,214,347

 
14,033,644

 

To view the Company's Fiscal 2018 Third Quarter Consolidated Financial Statements, related Notes to the Consolidated Financial Statements, and Management's Discussion and Analysis, please see the Company's filings, which will be available at www.sedar.com, www.sec.gov and on Oncolytics' website at http://www.oncolyticsbiotech.com/investor-centre/financials/.

About Pelareorep
Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in patients.





About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and adaptive immune responses. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements, including the Company's belief as to the potential and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; the collaboration between Merck and USC using pelareorep, including the timing, enrollment and potential benefits to the Company thereof; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

Company Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
858-886-7813
mmoore@oncolytics.ca  

Investor Relations
Robert Uhl
Westwicke Partners
858-356-5932 
robert.uhl@westwicke.com 
Media Contact
Jason Spark
Canale Communications               
619-849-6005
jason@canalecomm.com